Article
Oncology
Jianqiu Wu, Yuqin Song, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, Jun Luo, Liling Zhang, Hongwei Xue, Qingyuan Zhang, Weiwei Wang, Chunxia Chen, Jifeng Feng, Jun Zhu
Summary: Camrelizumab demonstrates potent antitumor activity, good tolerability, and manageable safety in patients with relapsed or refractory classical Hodgkin lymphoma. Extended follow-up shows durable response, long survival, and rare occurrence of new side effects, with reactive capillary endothelial proliferation being the main observed adverse event.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Yuqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Lihong Liu, Guohua Yu, Yu Hu, Zheng Zhao, Ligen Liu, Hongwei Xue, Jun Luo, Bai He, Xiaoping Jin, Min Zhao, Baiyong Li, Yu Xia, Jun Zhu
Summary: This study evaluated the efficacy and safety of a novel anti-PD-1 antibody, penpulimab, in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL). The results showed that penpulimab demonstrated good response rates and survival outcomes in patients, with some adverse reactions during treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ningjing Lin, Mingzhi Zhang, Hai Bai, Hui Liu, Jie Cui, Xiaoyan Ke, Huilai Zhang, Lihong Liu, Dongmei Yan, Yongsheng Jiang, Aimin Zang, Junyuan Qi, Li Wang, Zhuogang Liu, Bing Xu, Ying Zhang, Zhihui Zhang, Xielan Zhao, Chunhong Hu, Shenmiao Yang, Hui Zhou, Jinsheng Shi, Zonghong Shao, Ying Xiang, Jiman Zhu, Yuqin Song, Jun Zhu
Summary: GLS-010 (zimberelimab) demonstrates effectiveness and safety in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. The objective response rate assessed by an independent radiology review committee was 90.6%, with a complete response rate of 32.9%. The 12-month progression-free survival and overall survival rates were 78% and 99%, respectively.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Yujie Zhang, Zhichao Xing, Li Mi, Zhihui Li, Jingqiang Zhu, Tao Wei, Wenshuang Wu
Summary: Classical Hodgkin lymphoma, the most common type of HL, mainly affects people in certain age groups. A significant proportion of patients with refractory or relapsed cHL do not respond well to treatment. Exploring new predictive strategies and treatment measures may help improve the cure rate for these patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yang Liu, Chunmeng Wang, Xiang Li, Liang Dong, Qingming Yang, Meixia Chen, Fengxia Shi, Malcolm Brock, Miao Liu, Qian Mei, Jiejie Liu, Jing Nie, Weidong Han
Summary: The combination of camrelizumab and decitabine leads to longer progression-free survival in patients with relapsed/refractory cHL compared to camrelizumab monotherapy, showing superior efficacy and potential as a biomarker for treatment response in certain patient subgroups.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu
Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.
Article
Biochemistry & Molecular Biology
Rong Tao, Lei Fan, Yongping Song, Yu Hu, Wei Zhang, Yafei Wang, Wei Xu, Jianyong Li
Summary: The study demonstrated that sintilimab is effective and well tolerated in patients with relapsed/refractory extranodal NK/T cell lymphoma, with a low rate of adverse events. It could be a novel therapeutic approach for controlling this type of cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Oncology
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu
Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Summary: Achieving minimal disease status before autologous stem cell transplantation (ASCT) is crucial for Hodgkin lymphoma (HL) patients. This retrospective study evaluated the effectiveness and safety of the BEGEV regimen as a first salvage treatment prior to ASCT in HL patients. The results showed that the BEGEV regimen was able to induce complete response in a significant number of patients with limited toxicity, and did not impair peripheral blood stem cell mobilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Summary: This study evaluated the outcomes of single or tandem ASCT in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL), especially in high-risk patients. The results showed that tandem transplantation can significantly improve the progression-free survival rate in high-risk patients, but there was no significant difference in overall survival rate.
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Review
Biotechnology & Applied Microbiology
Selma Addou, Clementine Sarkozy, Julien Lazarovici, Stephane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurelien Marabelle, Jean-Marie Michot
Summary: Classical Hodgkin lymphoma is a neoplastic hematological disease with a high cure rate in early-stage patients but 15% of patients require new treatment strategies. Some documented cases show cancer remission following viral infections, leading researchers to investigate oncolytic viruses for treating Hodgkin lymphoma. Modern viral technologies and understanding of viruses' relationship with cancer could accelerate the development of effective viral oncolytic therapies.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Oncology
Huiqiang Huang, Rong Tao, Siguo Hao, Yu Yang, Hong Cen, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin, Liling Zhang, Haiyan Yang, Xiaojing Xing, Huilai Zhang, Yanyan Liu, Kaiyang Ding, Qinzhou Qi, Xiaoli Zhu, Dan Zhu, Siyuan Wang, Teng Fang, Hangjun Dai, Qingmei Shi, Jason Yang
Summary: This phase II study evaluated the efficacy and safety of sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL. The results showed that sugemalimab demonstrated robust and durable antitumor activity in R/R ENKTL and was well tolerated.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Pauline Brice, Eric de Kerviler, Jonathan W. Friedberg
Summary: Classical Hodgkin lymphoma is a relatively common lymphoma that is generally considered highly curable with standard first-line chemotherapy and radiotherapy, although some patients may not be cured or may experience late toxic effects leading to premature death. Recent changes in the gold standard of chemotherapy, now often including immunotherapy in relapse settings, have further impacted treatment outcomes.
Article
Hematology
Eleonora Calabretta, Martina di Trani, Francesco Corrado, Martina Sollini, Vanessa Cristaldi, Fabrizio Marino, Lodovico Terzi di Bergamo, Alessio Bruscaggin, Maria Cristina Pirosa, Stefania Bramanti, Arturo Chiti, Davide Rossi, Carmelo Carlo-Stella
Summary: This study aims to evaluate the predictive and prognostic value of ctDNA in relapsed/refractory Hodgkin lymphoma (cHL). The findings suggest that ctDNA genotyping can reflect gene mutations and pathways in cHL, while baseline ctDNA quantification and serial monitoring can serve as prognostic indicators. Additionally, integrating ctDNA quantification with iPET evaluation helps to identify patients at high risk of treatment failure.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Weiping Liu, Jiangmei Liu, Yuqin Song, Xiaopei Wang, Maigeng Zhou, Lijun Wang, Jun Ma, Jun Zhu
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2019)
Letter
Oncology
Yonghui Sun, Ning Ding, Yuqin Song, Zimo Yang, Wanli Liu, Jun Zhu, Yu Rao
Article
Oncology
Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai
Article
Biochemistry & Molecular Biology
Zhitao Ying, Xue F. Huang, Xiaoyu Xiang, Yanling Liu, Xi Kang, Yuqin Song, Xiaokai Guo, Hanzhi Liu, Ning Ding, Tingting Zhang, Panpan Duan, Yufu Lin, Wen Zheng, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Yan Xie, Chen Zhang, Weiping Liu, Lijuan Deng, Shunyu Gao, Lingyan Ping, Xuejuan Wang, Nina Zhou, Junqing Zhang, Yulong Wang, Songfeng Lin, Mierzhati Mamuti, Xueyun Yu, Lizhu Fang, Shuai Wang, Haifeng Song, Guan Wang, Lindsey Jones, Jun Zhu, Si-Yi Chen
Article
Oncology
Ningjing Lin, Wenjing Ku, Yuqin Song, Jun Zhu, Zheming Lu
Article
Oncology
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Liudi Yang, Rebecca Elstrom, Jane Huang, William Novotny, Vivian Wei, Jun Zhu
Article
Oncology
Zhitao Ying, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Feifei Qi, Yanping Ding, Xin-an Lu, Yuqin Song, Jun Zhu
MOLECULAR THERAPY-ONCOLYTICS
(2019)
Article
Oncology
Weiping Liu, Jiangmei Liu, Yuqin Song, Xinying Zeng, Xiaopei Wang, Lan Mi, Cai Cai, Lijun Wang, Jun Ma, Jun Zhu
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2019)
Article
Hematology
Yan Xie, Xiaopei Wang, Xin Leng, Wen Zheng, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Meng Wu, Yuqin Song, Ju Zhu
ANNALS OF HEMATOLOGY
(2020)
Article
Oncology
Liu Weiping, Ji Xinqiang, Song Yuqin, Wang Xiaopei, Zheng Wen, Lin Ningjing, Tu Meifeng, Xie Yan, Ping Lingyan, Ying Zhitao, Zhang Chen, Deng Lijuan, Wu Meng, Feng Feier, Leng Xin, Sun Yingli, Du Tingting, Zhu Jun
Article
Cardiac & Cardiovascular Systems
Weiping Liu, Mingzi Yang, Lingyan Ping, Yan Xie, Xiaopei Wang, Jun Zhu, Yuqin Song
Summary: The PBVD regimen showed high overall response rate and prolonged duration of response in patients with HL, with low cardiotoxicity rates. It can be an effective alternative for HL patients who are unable to undergo conventional doxorubicin treatment.
CARDIOVASCULAR TOXICOLOGY
(2021)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Hongye Gao, Xiaogan Wang, Yumei Lai, Chen Zhang, Lan Mi, Xinqiang Ji, Xiaopei Wang, Yuqin Song, Jun Zhu, Weiping Liu
Summary: This study retrospectively collected clinical data of lymphoma patients with synchronous solid tumors at Peking University Cancer Hospital & Institute between 2009 and 2019. The results showed that less than 50% of patients had identifiable solid tumors at baseline. The detection of solid tumors at different time points would affect the choice of treatment options and impact patient survival.
Article
Hematology
Honghao Gao, Ningjing Lin, Zhenyang Gu, Shihua Zhao, Xiaopei Wang, Shunzong Yuan, Yuqin Song, Jun Zhu, Wenrong Huang, Weiping Liu, Chunji Gao
Summary: This study aimed to investigate the effectiveness and safety of autologous hematopoietic stem cell transplantation (ASCT) in advanced extra-nodal NK/T-cell lymphoma (ENKTL) patients in first complete remission. The study found that patients who underwent ASCT had significantly better 2-year overall survival (OS) and 2-year progression-free survival (PFS) compared to those who only received chemotherapy. However, further prospective clinical trials are needed to confirm these findings.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
B. Bu, K. Yi, H. Wang, M. Yang, M. Wu, L. Ping, Y. Xie, J. Qiu, L. Zhao, D. Mei, X. Wang, Y. Song, J. Zhu, W. Liu